Literature DB >> 35711220

Three-dimensional-printed model of surgically resectable angioinvasive pulmonary mucormycosis.

Catherine T Byrd1, Devarsh Vyas2,3, H Henry Guo3, Natalie S Lui1.   

Abstract

Entities:  

Year:  2022        PMID: 35711220      PMCID: PMC9197082          DOI: 10.1016/j.xjtc.2022.04.013

Source DB:  PubMed          Journal:  JTCVS Tech        ISSN: 2666-2507


× No keyword cloud information.
3D-printed model of angioinvasive pulmonary mucormycosis. It is important to recognize CT findings of advanced but surgically resectable pulmonary mucormycosis. Customized 3D printing helps to highlight these imaging findings. Although rare, the incidence of pulmonary mucormycosis is rising. While combined antimicrobial and surgical treatment decreases mortality compared with medical therapy alone, nonspecific presentation often delays definitive diagnosis and therapy. This report presents characteristic computed tomography (CT) findings of pulmonary mucormycosis, enhanced by 3-dimensional (3D)-printed modeling. Early mucormycosis often forms a “CT halo sign”—a nodule or mass encompassed by ground-glass opacities. This can progress to a “reversed halo sign”—a ground-glass opacity encompassed by denser consolidation. Further progression can produce central tissue destruction with bordering hemorrhage, manifesting as cavitation with surrounding opacities., Although contained within one lobe initially, mucormycosis can cross fissures to involve multiple lobes. Patients who undergo surgery—a nonanatomic wedge resection for peripheral disease or lobectomy for central disease—have a survival benefit. A patient on immunosuppression after bilateral lung transplant presented with pleuritic pain, chills, and a right lower lobe consolidation on chest radiograph. The patient's CT images were representative of pulmonary mucormycosis (Figure 1, A, and Video 1) with central necrosis, surrounding consolidation, and ground-glass opacities (the reversed halo sign) centered in the right lower lobe. The CT was used to segment and create 3D computer-generated renderings (Figure 1, B), which served as the basis for the 3D-printed model (Figure 1, C, and Video 2) using multimaterial PolyJet technology (Stratasys).
Figure 1

Creation of 3-dimensional (3D) printed model of the reversed halo sign of late pulmonary mucormycosis. A, Sagittal view from computed tomography (CT) scan of the chest; B, computer-generated 3D visualization recreated from CT images; and C, 3D-printed model shows a cavitary lesion in the right lower lobe with surrounding areas of consolidation and extensions of ground-glass opacities peripherally that invade into the right middle lobe. The 3D-printed model shows the necrosis in brown, consolidation in dark maroon, ground-glass in light maroon, fissures in white, and pulmonary vessels and airways in tan colors; this model serves as an educational tool at our institution for mucormycosis pathogenesis.

Creation of 3-dimensional (3D) printed model of the reversed halo sign of late pulmonary mucormycosis. A, Sagittal view from computed tomography (CT) scan of the chest; B, computer-generated 3D visualization recreated from CT images; and C, 3D-printed model shows a cavitary lesion in the right lower lobe with surrounding areas of consolidation and extensions of ground-glass opacities peripherally that invade into the right middle lobe. The 3D-printed model shows the necrosis in brown, consolidation in dark maroon, ground-glass in light maroon, fissures in white, and pulmonary vessels and airways in tan colors; this model serves as an educational tool at our institution for mucormycosis pathogenesis. Mucormycosis infection was printed in brown/dark maroon for areas of necrosis and consolidation, and light maroon for surrounding ground-glass opacities that extend into the right middle lobe. The cavitary mass was resected by right lower lobectomy, with intercostal muscle flap over the bronchial stump. To maximize remaining parenchyma, the right middle lobe was preserved, and residual infection treated medically. The patient remains well 2 years later. This model serves as an institutional educational tool for diagnosis and treatment of pulmonary mucormycosis. This report contains no patient identifiable information, so the Stanford institutional review board did not review this study and patient consent for publication was not received.
  4 in total

1.  Cut it out! Thoracic surgeon's approach to pulmonary mucormycosis and the role of surgical resection in survival.

Authors:  Ashrit Multani; Rosyli Reveron-Thornton; Donn W Garvert; Carlos A Gomez; Jose G Montoya; Natalie S Lui
Journal:  Mycoses       Date:  2019-08-06       Impact factor: 4.377

Review 2.  Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis.

Authors:  Valliappan Muthu; Ritesh Agarwal; Sahajal Dhooria; Inderpaul Singh Sehgal; Kuruswamy Thurai Prasad; Ashutosh N Aggarwal; Arunaloke Chakrabarti
Journal:  Clin Microbiol Infect       Date:  2021-01-05       Impact factor: 8.067

3.  Pulmonary mucormycosis: serial morphologic changes on computed tomography correlate with clinical and pathologic findings.

Authors:  Bo Da Nam; Tae Jung Kim; Kyung Soo Lee; Tae Sung Kim; Joungho Han; Myung Jin Chung
Journal:  Eur Radiol       Date:  2017-08-10       Impact factor: 5.315

4.  Sequential morphological changes in follow-up CT of pulmonary mucormycosis.

Authors:  Ji Yung Choo; Chang Min Park; Hyun-Ju Lee; Chang Hyun Lee; Jin Mo Goo; Jung-Gi Im
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.